Neurelis, Inc. v. Lupin Inc.

I'll research this case thoroughly before writing the overview.

Good initial data. Let me verify the patent set for this docket, the parallel IPRs, and recent developments.

Case Overview and Background — Neurelis, Inc. v. Lupin Inc., No. 1:25-cv-01443-MN (D. Del.)

The parties. Neurelis, Inc. is a privately held, commercial‑stage neuroscience company (founded 2007; HQ 3430 Carmel Mountain Road, San Diego) that develops and sells CNS drugs, not an NPE or university licensee. Its franchise product is VALTOCO® (diazepam nasal spray), approved under NDA No. N211635 (Jan. 10, 2020) for acute treatment of seizure clusters/intermittent stereotypic episodes of frequent seizure activity in epilepsy patients; the FDA granted orphan‑drug exclusivity based on clinical superiority over rectal diazepam gel, and the label was expanded in 2025 to patients 2 years and older. Neurelis reported estimated 2025 net sales of $295–300M (more than double 2024), 30%+ EBITDA margins and $175M+ cash, with the Orange Book listing now at six patents extending exclusivity to October 2032 (Neurelis press release, Jan. 12, 2026). Its Rule 7.1 disclosure in this and the companion cases identifies China Medical System Holdings Limited as an "other affiliate" (Neurelis's China commercialization partner/investor), a useful reminder that plaintiff is a single‑product specialty pharma with concentrated exposure to generic entry, D.I. 5. Defendants are the Lupin group — Lupin Inc. (a Delaware corporation; Rule 7.1 parent identified as Nanomi B.V.), Lupin Limited (India; parent of Lupin Pharmaceuticals, Inc.) and Lupin Pharmaceuticals, Inc.; Lupin is one of the largest global generics manufacturers and a frequent Hatch‑Waxman defendant in Delaware (D.Del. 1:25-cv-01443 docket; Justia).

The accused product and asserted patents. The accused technology is Lupin's proposed generic VALTOCO, i.e., diazepam nasal spray at 5, 7.5 and 10 mg/spray, submitted in ANDA No. 220394; infringement is the § 271(e)(2)(A) act of filing the ANDA and Lupin's notified intent to launch on approval. Lupin's Paragraph IV notice letter dated May 27, 2025 (signed by outside counsel Deepro R. Mukerjee) certified that the claims of the '546, '414, '786 and '664 patents are invalid, unenforceable and/or not infringed (admitted in Lupin's answer in 1:25-cv-00821). A separate Lupin notice dated October 17, 2025 triggered this docket, and the complaint filed 45 days later asserts U.S. Patent Nos. 12,324,852 and 12,337,061 — as reflected in the Form AO‑120 patent report (D.I. 4) and the ANDA supplemental information (D.I. 3), and as independently reported in Robins Kaplan's Hatch‑Waxman bulletin (JD Supra, Q4 2025 ANDA cases). Both are method‑of‑treatment patents in the "Administration of Benzodiazepine Compositions" family, issued in 2025, and both claim priority to the same lineage that traces to a March 28, 2008 provisional:

• '852 — a method of treating bouts of intermittent, stereotypic seizure activity by administering a single 100 µL spray to one nostril of a stable solution containing diazepam, vitamin E, dodecyl maltoside, benzyl alcohol and ethanol, achieving 92.5–107.5% of the bioavailability of IV diazepam (claims 1–62 asserted) — expires 10/16/2032.
• '061 — a method of treating seizures by administering a stable non‑aqueous nasal spray containing diazepam, vitamin E, DMD, benzyl alcohol and ethanol with IV‑comparable bioavailability (independent claim 21 among claims 1–62) — expires 6/13/2032 (complaint analysis, Ex Parte). Note a metadata discrepancy: the case metadata lists 11,241,414 as the patent at issue in this docket, but the docket's own AO‑120/ANDA forms list only the '852 and '061. The '414 (issued Feb. 8, 2022; a "consisting of" nasal formulation of diazepam + tocopherols 30–95% w/w + ethanol/benzyl alcohol 10–70% w/w + n‑dodecyl β‑D‑maltoside, Orange Book expiry 3/27/2029) is instead being litigated against Lupin in the consolidated companion action 1:25-cv-00821-MN (D.I. 4 there reports '414, '786, '664) and is the subject of Padagis's instituted IPR2025‑00465. Treat the '414 as part of the same coordinated campaign, not as the patent pleaded in this docket.

Procedural posture and why Delaware matters. Filed Nov. 26, 2025 and assigned to Judge Maryellen Noreika (Wilmington division); the case was associated with lead case 1:24-cv-00562-MN on Jan. 23, 2026 alongside the other Neurelis–Padagis/Lupin ANDA actions, and the Rule 16 order followed the same day (D.I. 14): fact discovery closed Apr. 10, 2026, Markman hearing set July 22, 2026, opening/rebuttal/reply expert reports Aug.–Nov. 2026, expert discovery Dec. 2, 2026, and a five‑day bench trial on Mar. 1, 2027 (the court separately calendared a 4/26/2027 trial in the lead case); the 30‑month stay runs to Nov. 27, 2027 (D.I. 3). Lupin Inc. and Lupin Pharmaceuticals answered and counterclaimed on Dec. 22, 2025 (D.I. 9, 10); Neurelis answered the counterclaims Jan. 12, 2026 (D.I. 11). No jury demand was made — normal in ANDA practice. Venue is uncontroversial and essentially automatic: Lupin Inc. is a Delaware corporation, satisfying § 1400(b), and the District of Delaware remains the dominant Hatch‑Waxman forum, with Judge Noreika running one of the busiest ANDA dockets and a standardized form scheduling order that pushes cases to a bench trial in roughly 15 months — here, well before the statutory stay would expire. (I found no public report of a claim‑construction ruling following the July 22, 2026 Markman hearing; that remains unverified as of today.)

Why the case is notable. Three things make this more than a routine ANDA suit. First, it is a rolling, patent‑by‑patent exclusivity strategy. Neurelis sued Padagis on the '546/'414/'786 in May 2024 (1:24-cv-00562), added Lupin and the '664 patent in July 2025 (1:25-cv-00821), then filed new suits on the newly issued '852/'061 against both Padagis (1:25-cv-01228, Oct. 3, 2025) and Lupin (this docket, Nov. 26, 2025), followed by later waves on the '400 patent (1:26-cv-00258 and Neurelis v. Padagis, 1:26-cv-00401, Apr. 8, 2026). The practical effect is that generics that certified against patents expiring in March 2029 (and whose earliest‑listed patents expired in May–July 2025) now face method patents running to October 2032, forcing successive 30‑month stays. Second, the validity fight is being run in parallel at the PTAB on the same priority theory. Padagis filed IPR2025‑00464/‑465/‑466 against the '546, '414 and '786 (Jan. 17, 2025); Neurelis's Fintiv request was rejected by Acting Director Stewart's July 16, 2025 referral decision — designated informative on Jan. 9, 2026 — because the examiner's contrary priority finding (versus the Board's earlier holding in Aquestive v. Hale Biopharma, IPR2019‑00451, that the claims lacked '558‑provisional support and were obvious over Gwozdz PCT + Meezan) suggested material Office error (Jones Day / PTAB Litigation Blog). All three IPRs were instituted, with a projected final written decision of Sept. 17, 2026. Neurelis has since tried to salvage the family by moving for a certificate of correction adding a Joint Research Agreement disclosure to trigger the pre‑AIA § 103(c)(2)(C) safe harbor and eliminate Gwozdz; the Board denied leave (Feb. 6, 2026) and denied rehearing (Paper 39, Mar. 20, 2026), emphasizing a seven‑year delay prejudicing the time‑barred petitioner, and Neurelis filed a statutory disclaimer on the '546 patent on Jan. 2, 2026 (Board rehearing decision). Because Lupin's Paragraph IV certifications rest on the same Gwozdz‑based art, the PTAB's priority jurisprudence is effectively a shadow merits ruling for this litigation — though I found no IPR petition against the '852 or '061 patents themselves (their method‑of‑use claim format may make them harder to attack administratively, which is presumably the point). Third, market impact: this is a ~$300M, orphan‑exclusivity‑protected, single‑product company defending what is essentially its only revenue stream against coordinated generic challengers, in a therapeutic category where intranasal rescue therapy is displacing rectal gel — so an adverse outcome on the '852/'061 would accelerate generic entry roughly three years earlier than the formulation patents would otherwise permit.

Caveats: party names, court, case number and the docket facts above are drawn from the case metadata, the D.Del. docket (D.I. 1, 3–5, 9–14) and the sources cited; the patent list discrepancy noted above is real and unresolved in the public record I could reach; I could not verify Lupin Limited's appearance, any post‑Markman ruling, or the firm affiliations of individual counsel beyond those appearing on the filings, and the forecast/exclusivity figures are Neurelis's own estimates.

I'll research this case systematically. Let me start with several parallel searches.

Let me pull the actual dockets and complaint documents for this case and its related actions.

Caveat on the patents at issue (read first)

The metadata for this case lists U.S. Patent No. 11,241,414. The docket record for 1:25-cv-01443-MN, however, shows the operative complaint and the ANDA/Trademark report covering U.S. Patent Nos. 12,324,852 (issued 2025-06-10) and 12,337,061 (issued 2025-06-24) — both "Administration of benzodiazepine compositions" and both expiring with PTA in 2032 (D.I. 3, D.I. 4, filed 2025-11-26, via Justia docket and Docket Alarm). The '414 patent is in this family and is in suit — but in the consolidated lead action, not in this docket — and it is the subject of a parallel IPR. I cover both below and flag which facts belong to which docket.

---

Underlying ANDA/patent backdrop

• VALTOCO® (diazepam nasal spray), Neurelis's branded product, was approved by FDA on 2020-01-10 (NDA 211635; 5/7.5/10 mg strengths). No generic had been approved as of the last public FDA listing (2026-03-11) (Drugs.com).
• The Orange Book family includes the '546, '414, '786, '664, '852, '061 and '400 patents, all "Administration of benzodiazepine compositions" and all asserting the 2008-03-28 priority family (Pharsight/GreyB).
• Lupin's accused product is ANDA No. 220394 (generic VALTOCO, 5 mg, 7.5 mg and 10 mg/spray).
• Lupin sent Neurelis three Paragraph IV notice letters: (1) 2025-05-27 (covering '414, '786, '664); (2) 2025-10-17 (covering '852 and '061 — the trigger for this case); (3) 2026-02-04 (covering '400) (complaint PDF, dedc25cv1443C.pdf; dedc26cv0258C.pdf; ParagraphFour case tracker).

Chronology for 1:25-cv-01443-MN (Neurelis v. Lupin)

1. Filing & initial pleadings

• 2025-10-17 — Lupin's Second Notice Letter (Paragraph IV certification against the '852 and '061 patents), executed by Deepro Mukerjee as agent for service (Compl. ¶¶33–34).
• 2025-11-26 — Neurelis files the complaint (D.I. 1) with Exhibits A and B (the notice letters) and a Notice of Related Actions. Two counts: infringement of the '852 patent (method claim, single 100 µL spray of a "consisting of" diazepam/vitamin E/dodecyl maltoside/benzyl alcohol/ethanol formulation achieving 92.5–107.5% of IV diazepam bioavailability) and of the '061 patent, each under § 271(e)(2)(A), plus §§ 271(a)/(b)/(c), willfulness, and a § 271(e)(4) request for a delayed approval date. Same date: ANDA supplemental information form (D.I. 3; 30-month stay deadline 2027-11-27), patent report (D.I. 4), Rule 7.1 disclosure (D.I. 5), summonses (D.I. 6).
• 2025-12-01 — Summonses returned executed on Lupin Inc. and Lupin Pharmaceuticals, Inc. (answer due 2025-12-22) (D.I. 7–8).
• 2025-12-03 — Case assigned to Judge Maryellen Noreika (MN).
• 2025-12-22 — Lupin Inc. and Lupin Pharmaceuticals, Inc. file their Answer and Counterclaims (D.I. 9), plus a Rule 7.1 disclosure identifying Lupin Limited as parent of Lupin Pharmaceuticals and Nanomi B.V. as parent of Lupin Inc. (D.I. 10). Note: Lupin Limited has not appeared and no proof of service on it appears on the docket; in the companion case Lupin denied that Lupin Ltd. and Lupin Pharmaceuticals were proper parties (Lupin's answer in 25-cv-821) — the same jurisdictional line is likely in play here (the '143 counterclaim text itself is not public on the free dockets, so treat as inference).
• 2026-01-12 — Neurelis's Answer to Counterclaim (D.I. 11).

2. Scheduling and case association

• 2026-01-12 — Oral Order (D.I. 12) directing the parties to confer on a scheduling order and giving Noreika's standard ANDA guidance: final infringement/invalidity (and non-infringement/validity) contentions at the close of fact discovery, with alternative contentions under both sides' proposed constructions; joint claim-construction chart and brief timing; and a further bench trial date of 2027-04-26.
• 2026-01-21 — Joint letter and proposed consolidated scheduling order (D.I. 13).
• 2026-01-23 — Scheduling Order entered (D.I. 14) and the case associated with lead case 1:24-cv-00562-MN (D.I. 15 entry). Deadlines:
  • Joinder / amended pleadings: 2026-03-06
  • Fact discovery close: 2026-04-10
  • Claim construction: opening brief 2026-05-15; answering 2026-05-29; reply 2026-06-12; surreply 2026-06-26; joint C.C. brief 2026-07-01
  • Markman hearing: 2026-07-22 (Courtroom 4A, Noreika)
  • Opening expert reports 2026-08-26; rebuttal 2026-10-07; reply 2026-11-04; expert discovery close 2026-12-02
  • Daubert motions 2027-01-08; answering brief 2027-01-22; reply 2027-01-29
  • Pretrial conference 2027-02-22; 5-day bench trial starting 2027-03-01 (with the alternative 2027-04-26 date noted above)
    (Docket Alarm event list)

3. Pre-trial motions of substance

• No motion to dismiss, transfer, or stay was filed in this docket as of the last public docket pull. Lupin answered on the merits rather than moving. No stay pending the Padagis IPRs appears either.
• Note the court's standard ANDA practice in the lead case: "Absent agreement between the parties, and prior approval from the Court, the Court will not hear case dispositive motions in ANDA cases" (Ex. 2002, 24-cv-562 D.I. 20 at 10) — so summary judgment is expected to be unavailable absent leave.
• No JMOL/new-trial/fee motions can yet exist: the case has not been tried.

4. Claim construction (Markman)

• Claim construction is fully briefed / heard: the Markman hearing was scheduled for 2026-07-22, and the joint claim construction brief was due 2026-07-01. I found no public ruling, order, or transcript as of 2026-09-14. Practically, the disputed terms are the closed transitional phrase "consisting of" and the modifier "about" as applied to the weight-percentage ranges, plus the pharmacokinetic/bioavailability limitations in the '852 '061 method claims (see the complaint-analysis discussion of these terms at Ex Parte AI Lab). This should be treated as the next major inflection point.

5. Discovery milestones of strategic significance

• 2026-03-06 — joinder/amended-pleading cutoff (no amendments publicly docketed).
• 2026-04-10 — fact discovery closed. Under the court's order, final infringement and invalidity contentions (including contentions under both sides' competing constructions) were due around this date — the point at which Neurelis's accused-formulation proof and Lupin's formulation/PK evidence were locked in.
• 2026-08-26 — opening expert reports due (just passed); rebuttal 2026-10-07; reply 2026-11-04; expert discovery closes 2026-12-02.
• The principal evidentiary battleground is compositional identity: the exact excipients and w/w percentages in Lupin's ANDA product versus the closed "consisting of" claims of the '852/'061 patents (and whether any unrecited excipient takes the product outside the claims).

6. Trial, verdict, post-trial motions

• None yet. Bench trial (no jury demand) is set for 2027-03-01 (5 days), with a reserved alternative date of 2027-04-26; pretrial conference 2027-02-22. No verdict, JMOL, new-trial, or fee motion exists.

7. Settlement / dismissal / judgment / appeal — present posture

• No settlement, consent judgment, dismissal, or appeal. The case is active, consolidated into (associated with) lead case 1:24-cv-00562-MN, in fact-and-expert discovery, with a 30-month FDA stay of Lupin's ANDA running to 2027-11-27.

Parallel PTAB proceedings and their effect

• IPR2025-00464 ('546), IPR2025-00465 ('414), IPR2025-00466 ('786) — all petitioned by Padagis US LLC (not Lupin) on 2025-01-17, all instituted for trial on 2025-09-16, with the oral hearing/trial set for 2026-06-16 (Pharsight activity log; ParagraphFour tracker). IPR2025-00465 is the IPR on the '414 patent listed in this case's metadata.
• Neurelis's preliminary responses (e.g., in the '546 IPR) argued that the Gwozdz PCT's "penetration enhancer" disclosure lacks support in the 2008 Gwozdz provisional and so is not prior art, and that the petitions failed to supply an adequate motivation to combine with Meezan — citing In re Riggs, 131 F.4th 1377 (Fed. Cir. 2025) (Patent Owner Preliminary Response, PTACTS). The Board nonetheless instituted all three.
• Effect on the litigation: These IPRs target the patents asserted in the consolidated lead case ('546, '414, '786) — not the '852/'061 patents pleaded in this docket, which the Board has not addressed. The instituted IPRs created pressure to avoid a stay in Delaware; the lead case's joint claim construction brief (filed 2025-08-22 in 24-cv-562) was later used as an exhibit in IPR2025-00464 (EX2050, 2026-01-05), suggesting the Board record is being used to police Neurelis's claim-scope positions and vice versa. No § 315 estoppel runs against Lupin, since Lupin is not a petitioner — a notable asymmetry between the co-defendants.
• Statutory final written decisions in all three IPRs would be due on or about 2026-09-16 (one year from institution). I could not verify public FWD outcomes as of today's date; treat the FWD result as pending/unconfirmed.
• Historical note: Neurelis's earlier '876 patent survived a 2019 Aquestive IPR challenge — two institution denials (2019-08-01) and an FWD (2020-08-06) (Pharsight).

Related/consolidated dockets (context for the "final disposition" picture)

Sources for the table: Justia docket search — Lupin parties; CourtListener complaint in 1:26-cv-00401; ParagraphFour tracker.

Bottom line

For 1:25-cv-01443-MN the only truly "legal developments" to date are pleadings-stage: the 2025-11-26 complaint on the '852/'061 patents (30-month stay to 2027-11-27), Lupin's 2025-12-22 answer and counterclaims by Lupin Inc./Lupin Pharmaceuticals (with Lupin Limited a named non-appearing defendant), Neurelis's answer to counterclaims (2026-01-12), and the 2026-01-23 scheduling order associating the case with lead case 1:24-cv-00562-MN and setting fact-discovery close (2026-04-10), a Markman hearing (2026-07-22, outcome not publicly confirmed), and a bench trial for 2027-03-01. There are no dispositive-motion, stay, trial, or post-trial events, and no settlement or appeal. The nearest thing to a merits ruling in this patent family is the three Padagis IPRs on the '546/'414/'786 patents, all instituted 2025-09-16, with FWDs falling due around 2026-09-16 — outcomes unverified. The most significant unresolved factual questions for a follow-up check are (a) whether the Markman ruling issued after the 2026-07-22 hearing, and (b) the FWD results in IPR2025-00464/465/466.

I'll research the counsel of record for Neurelis, Inc. in this case.

Let me pull the docket appearance details and the complaint signature block.

Counsel of Record — Neurelis, Inc. (Plaintiff), Neurelis, Inc. v. Lupin Inc., No. 1:25-cv-01443-MN (D. Del.)

Important threshold caveat: This is a young docket (complaint filed 11/26/2025) and the free docket mirrors I could reach show a very thin appearance record. I could not retrieve a PACER docket sheet directly, and I found no pro hac vice motion, no entry of appearance, and no signature block from this specific docket in the public sources I could reach. Below I separate what is documented on the docket mirrors from what is inferable from the related Neurelis ANDA cases, which are being consolidated under lead case 1:24-cv-00562-MN.

---

1. Confirmed on the docket (plaintiff's side)

Sources: Justia docket for 1:25-cv-01443 ("Represented By: Ethan Haller Townsend") — https://dockets.justia.com/docket/delaware/dedce/1:2025cv01443/91297; PacerMonitor docket for Neurelis v. Amneal Pharmaceuticals LLC, 1:26-cv-00261 (D. Del.) — https://www.pacermonitor.com/public/case/63525453/Neurelis,_Inc_v_Amneal_Pharmaceuticals_LLC_et_al; Law360 attorney page for Ethan H. Townsend (Wilmington, DE) — https://www.law360.com/firms/mcdermott-will/attorneys/ethan-h-townsend; Super Lawyers profile (lists the same Wilmington address) — https://profiles.superlawyers.com/delaware/wilmington/lawyer/ethan-h-townsend/f6a02a85-02bd-4e62-a22e-490f80a14ae3.html.

Firm-name caution: Every database I hit spells the firm "McDermott Will & Schulte LLP." That is not the name of any firm I can verify independently; the well-known firm with a Wilmington office and this attorney roster is McDermott Will & Emery LLP. I am flagging the discrepancy rather than resolving it — treat the exact firm entity as unverified.

2. Reported lead / out-of-state counsel (documented in the related Neurelis cases, not yet confirmed in 1:25-cv-01443)

Sources: ParagraphFour Valtoco® case entry ("Plaintiff Lawyer/Firm: Michael Sitzman/DLA Piper") — https://paragraphfour.com/members/parryashford/activity/11704/; PacerMonitor Amneal docket (same URL as above); complaint text confirming the related dockets are the Padagis/Lupin/Amneal Valtoco® actions — https://paragraphfour.com/wp-content/uploads/2024/05/dedc25cv1443C.pdf.

3. What I could not verify (do not treat as established)

• No entry of appearance or PHV motion retrieved for docket 1:25-cv-01443 itself. The Justia snapshot for this docket lists only the complaint, ANDA form, Rule 7.1 disclosure, patent report, and summons — nothing after December 2025 in the free mirror.
• No signature block. I could not open the complaint PDF's signature page, so I cannot confirm which attorney/firm signed the 11/26/2025 complaint in this docket.
• The DLA Piper connection is inferred from the Padagis case and reported by a third-party (ParagraphFour) site, not from this docket. It is possible the Neurelis team spans two firms (McDermott + DLA Piper) or that the lineup has changed; confirm against the live PACER docket sheet and any consolidation order (entered ~1/23/2026).
• Some AI-generated aggregator content (e.g., the "exparte" complaint analysis) states "Plaintiff's Counsel: McDermott Will & Schulte LLP" for this docket. That is consistent with the docket-mirror data but is a secondary source and repeats the same suspect firm name.

4. Case-specific note that bears on the caption/patents

The metadata for this matter lists U.S. Patent 11,241,414 as the patent at issue, but the complaint filed in 1:25-cv-01443 on 11/26/2025 asserts U.S. Patent Nos. 12,324,852 (claims 1–31) and 12,337,061 (claims 1–62) against Lupin's ANDA No. 220394 — the '414 patent belongs to the earlier Padagis I action (1:24-cv-00562). See the docket's "Report to the Commissioner of Patents" entry (patent numbers 12,324,852 and 12,337,061) at https://dockets.justia.com/docket/delaware/dedce/1:2025cv01443/91297, the complaint text at https://paragraphfour.com/wp-content/uploads/2024/05/dedc25cv1443C.pdf, and JD Supra's Q4-2025 new ANDA case roundup listing "Neurelis, Inc. v. Lupin Inc., 25-1443 (D. Del.) … 12,324,852; 12,337,061."

---

Recommended next step for a definitive answer: pull the live PACER docket for 1:25-cv-01443-MN (and the consolidation order in lead case 1:24-cv-00562-MN) and check the "Attorneys" tab / entries of appearance and PHV orders. That will confirm whether the Sitzman–Best–Tobin–Hurley–Noorassa group has been admitted here, and will fix the exact name of the Townsend firm.

I'll research the docket and counsel for the defendant in this case.

Now let me find the specific counsel appearances and the answer filed by Lupin.